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ABSTRACT: Intoxication by organophosphate (OP) nerve
agents and pesticides should be addressed by efficient, quickly
deployable countermeasures such as antidotes reactivating
acetylcholinesterase or scavenging the parent OP. We present
here synthesis and initial in vitro characterization of 14
imidazole aldoximes and their structural refinement into three
efficient reactivators of human butyrylcholinesterase (hBChE)
inhibited covalently by nerve agent OPs, sarin, cyclosarin, VX,
and the OP pesticide metabolite, paraoxon. Rapid reactivation
of OP−hBChE conjugates by uncharged and nonprotonated
tertiary imidazole aldoximes allows the design of a new OP
countermeasure by conversion of hBChE from a stoichio-
metric to catalytic OP bioscavenger with the prospect of oral
bioavailability and central nervous system penetration. The enhanced in vitro reactivation efficacy determined for tertiary
imidazole aldoximes compared to that of their quaternary N-methyl imidazolium analogues is attributed to ion pairing of the
cationic imidazolium with Asp 70, altering a reactive alignment of the aldoxime with the phosphorus in the OP−hBChE
conjugate.
■ INTRODUCTION
The recent massive exposure of Syrian citizens to the nerve gas
organophosphate (OP) sarin fatally injured hundreds,1 because
of the lack of appropriate antidote intervention. It vividly
illustrated an immediate need for effective, affordable, and easily
administered countermeasures for rapid protection of large
populations from OP exposure. Currently approved antidotal
therapies for the treatment of OP poisoning in humans
encompass intramuscular injections of pyridinium aldoximes,
2PAM, HI6, obidoxime, toxogonin, or similar agents2,3
combined with a muscarinic acetylcholine receptor antagonist
(atropine) and an anticonvulsant (benzodiazepine). Alterna-
tively, an intravenously injected highly purified human
butyrylcholinesterase (hBChE) can serve as a scavenging
agent for the organophosphate in the circulation4−7 that is
effective both pre- and post-OP exposure.7,8
Pyridinium aldoxime therapy, developed nearly 60 years ago
in the seminal work of Wilson and colleagues,9 is directed
toward nucleophilic reactivation of acetylcholinesterase
(AChE) covalently inhibited by OPs to restore catalytic
hydrolysis of the neurotransmitter acetylcholine (ACh).
Protection by pyridinium aldoximes requires parenteral
administration and is limited by their rapid elimination and
inability to cross the blood−brain barrier. The OPs are
lipophilic, become sequestered in lipids where they leach
from tissues, and thereby allow residual concentrations to
persist. Accordingly, antidotal therapy may require repeated
administration to sustain appropriate concentrations in target
tissues.
Intravenous injection of purified hBChE affords the potential
of covalently conjugating the parent OP molecules distributed
in the circulation, thus protecting target tissue AChE from OP
inhibition. The molecular weight ratio of hBChE to OP
forming the OP−hBChE conjugate can be as high as 500−600,
so a large mass of BChE is required for it to be an effective
scavenger. While proven to be effective in animal studies,
stoichiometric scavenging in plasma by hBChE therapy is
limited by cost and the practicalities of wider administration to
an exposed or potentially exposed population.
Joint administration of an efficient oxime reactivator of the
OP−hBChE conjugate and purified hBChE protein to assist
catalysis and turnover of the offending OP in theory should
reduce the amount of hBChE needed for efficient protection by
establishing a “catalytic bioscavenger” system.10 We recently
demonstrated the feasibility, both in vitro and in vivo, of a
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catalytic bioscavenger composed of purified hBChE and a
cationic non-pyridinium aldoxime, TAB2OH, with selectivity
for BChE reactivation.11 While the catalytic bioscavenger shows
a decrease in the size of administered effective hBChE doses,
the net protective effects of our catalytic bioscavenger were
small because of the relatively low reactivation potency of
TAB2OH. Nevertheless, this oxime is to the best of our
knowledge the fastest characterized BChE reactivator reported
in the literature.
In this study, we follow up on our earlier observation that
simple N-alkyl imidazole aldoximes can be good reactivators of
hBChE12 and design more effective hBChE reactivators.
Although tertiary imidazole-based aldoximes have not been
previously described in the literature as cholinesterase
reactivators, quaternary imidazolium aldoximes were extensively
studied as mono-oxime OP−AChE reactivators13−18 and also as
bis-oximes in combination with pyridinium and quinuclidinium
oximes.19−21 Some of these compounds were characterized as
promising for reactivation of tabun- and soman-inhibited
AChE, both in vitro and in vivo. Reactivation of OP-inhibited
BChE by either tertiary or quaternary imidazole-based
aldoximes, on the other hand, had not been described in the
literature.
Herein, we thus characterize in vitro reactivation properties of
a family of uncharged tertiary imidazole aldoximes and their
quaternary methylimidazolium analogues against four different
OP−hBChE conjugates resulting from sarin, cyclosarin, VX,
and paraoxon inhibition of BChE and AChE and show
structural features necessary for efficient OP−hBChE conjugate
reactivation. The absence of charge in some of these tertiary
imidazole aldoximes bears the promise of reasonable oral
bioavailability and retention in tissue as well as potential for
central nervous system (CNS) penetration despite some agents
having limited solubility. The quaternary analogues are
expected to have smaller volumes of distribution and higher
initial plasma concentrations.
■ RESULTS AND DISCUSSION
Chemistry. On the basis of our observation that simple N-
alkyl-substituted imidazole aldoximes are good reactivators of
OP−hBChE conjugates,12 we synthesized a series of imidazole-
2-aldoxime derivatives substituted at N1. This was achieved by
alkylation of formylimidazole (1) with the requisite bromide or
mesylate, followed by treatment with hydroxylamine as shown
in Scheme 1. Using this protocol, a diverse array of aliphatic,
aromatic, and unsaturated substituents were incorporated into
the N1 position of the imidazole ring (compounds 3−10).
Next, we sought to improve water solubility and nucleophil-
icity of oxime derivatives via the preparation of quaternary salts
by methylating the N3 atom of the imidazole ring. Thus, the
quaternization was conducted by reacting selected correspond-
ing mono-oximes with iodomethane to deliver compounds 11−
14.
In addition to the 12 imidazole compounds, two cationic
mono-oxime derivatives were synthesized. For the preparation
of 17 and 18 (Scheme 2), formylimidazole 1 was first reacted
Scheme 1
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with 1,3-dibromopropane in N,N-dimethylfomamide (DMF)
using K2CO3 as a base while being stirred at room temperature
overnight to obtain 1-(3-bromopropyl)-1H-imidazole-2-carbal-
dehyde (15). Treatment of 15 with hydroxylamine and
Na2CO3 at room temperature afforded 1-(3-bromopropyl)-
1H-imidazole-2-carbaldehyde oxime (16). Heating oxime 16
with pyridine derivatives at 50 °C afforded 17 and
isonicotinamide derivative 18.
Initial Selection of Oxime Structures. Our previously
published screen of 135 uncharged oxime reactivators12
revealed that simple N-alkyl-substituted imidazole aldoximes
were good reactivators of OP−hBChE conjugates. That study
Scheme 2
Table 1. Reactivation Rate Constants of 0.67 mM N-Alkyl-Substituted Imidazole Aldoximes for OP−hBChE Conjugates
Formed by Inhibition of hBChE by Paraoxon and Nonvolatile Analogues of Sarin, Cyclosarin (CS), and VXa
aThe table shows the dependence of reactivation on the length of the oxime N-alkyl chain, for the five RS oximes,12 and oxime 10. The normalized
average (Norm. Avrg) kobs was calculated by averaging four kobs values for individual OPs, each expressed as a percentage of the average kobs of all (six
in this table) different oximes for that single OP. Experiments were performed at 37 °C in 0.1 M phosphate buffer (pH 7.4) in duplicate.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm401650z | J. Med. Chem. 2014, 57, 1378−13891380
was, however, focused on identifying optimal uncharged
reactivators of OP−hAChE conjugates; imidazole aldoximes
did not surface as optimal candidates. Herein we revisit OP−
hBChE conjugate reactivation by imidazole aldoximes and
analyze their potencies for reactivation of four individual OP−
hBChE conjugates, three identical to those obtained by nerve
agent sarin, cyclosarin, and VX inhibition and the fourth
obtained by paraoxon inhibition. The nerve agent OP−-hBChE
conjugates were prepared using Flu-MPs, low-toxicity nerve
agent analogues yielding OP−hBChE covalent conjugates
identical with the ones formed upon inhibition with nerve
agents. The first-order reactivation rate constants at a single
concentration (0.67 mM) of six initial oximes determined
under physiological conditions [0.1 M phosphate buffer (pH
7.4) at 37 °C] are listed in Table 1. It appears that the length of
the alkyl chain does affect reactivation rates. The N-pentyl
derivative RS-113B appeared as the most efficient reactivator of
the four conjugates, while shortening or lengthening the alkyl
chain oximes generally decreased efficiency. This trend was
most evident for VX and paraoxon. Reactivation rate constants
for the sarin-derived conjugate peaked at the smaller N-propyl
derivative RS-115B, and reactivation of the largest OP−hBChE
conjugate, generated by cyclosarin inhibition, was the fastest of
all conjugates and for all oximes with a slight preference for the
Table 2. Reactivation Rate Constants of 0.67 mM N-Alkyl-Substituted Imidazole and Imidazolium Aldoximes for OP−hBChE
Conjugates Formed by the Inhibition of hBChE by Paraoxon and the Nonvolatile Analogues of Sarin, Cyclosarin (CS), and VXa
aThe table shows the dependence of reactivation on the substitution at the terminus of the substituted N-alkyl chain. Oximes are ordered by the
normalized average (Norm. Avrg) kobs (for a description and experimental conditions, see Table 1). Values for 2PAM were not included in the
evaluation of the kobs average.
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longest N-alkyl derivative, 10. Because, of six studied imidazole
oximes, the N-pentyl imidazole RS-113B appeared to be the
most universal efficient reactivator of the four OP−hBChE
conjugates, it was selected as a template for further
optimization.
Optimization of Oxime Structures. On the basis of the
RS-113B structure, seven uncharged and three monocationic
mono-oxime derivatives with varying substitutions of the alkyl
chain were prepared (Table 2). Their reactivation potencies at a
concentration of 0.67 mM were compared to the potencies of
RS-113B and of a very short N-alkyl derivative, 9 (Table 2).
The simple introduction of a double bond at the end of the N-
pentyl alkyl chain yielded the most efficient oxime reactivator 3;
it was on average 3-fold faster than RS-113B but particularly
efficient for reactivation of cyclosarin, sarin, and VX conjugates
of hBChE. Equally efficient was the N-dimethylbutyl imidazole
4; its high efficiency was drastically reduced by elimination of a
single methyl to yield 6. General trends for 13 tested imidazole
oximes listed in Table 2 seem to favor a hydrophobic group
positioned four methylenes from the imidazole ring. Inserting
Table 3. Reactivation Rate Constants of 0.67 mM N-Alkyl-Substituted Imidazole and Imidazolium Aldoximes for OP−hBChE
Conjugates Formed by the Inhibition of hBChE by Paraoxon and Analogues of Sarin, Cyclosarin (CS), and VXa
aThe table shows the dependence of reactivation on the substitution at the end of the oxime N-alkyl chain. For a description of Norm. Avrg and
experimental conditions, see Table 1. Values for 2PAM, TAB2OH, HI6, MMB4, TMB4, and obidoxime were not included in the evaluation of the
kobs average.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm401650z | J. Med. Chem. 2014, 57, 1378−13891382
an azido group to terminate the alkyl chain (compounds 7 and
8) was counterproductive for reactivation for all OPs.
Furthermore, introduction of positive charge generally reduced
the reactivation efficacy. For example, quaternization of
imidazole into the N-methyl imidazolium ring of RS-113B to
yield 11 reduced the reactivation efficiency by ∼1 order of
magnitude, except for that of the more bulky cyclosarin
conjugate; its reactivation efficiency was enhanced. Introduc-
tion of pyridinium in place of a phenyl ring of 5, to yield 17,
resulted in a similar pattern. Additional small modifications of
the pyridinium ring in 17 to yield 18 decreased the reactivation
efficiency.
Of the 10 tested RS-113B analogues from Table 2, the two
highest-ranking reactivators 3 and 4 were markedly superior for
all OP−hBChE conjugate combinations, on average by 4-fold,
and significantly better than common reference oximes, 2PAM,
HI6, TMB-4, MMB-4, and toxogonin (Table 3).
BChE Reactivation Potencies of Three Selected
Imidazole Aldoximes and Their N-Methyl Imidazolium
Analogues. Along with two highest-ranking reactivators from
Table 2 (oximes 3 and 4), oxime 5 was selected for further
structural refinement. Although quaternization of RS-113B, our
initial lead from Table 1, had generally negative effects on
reactivation potency [conversion of RS-113B into 11 (Table
2)], we decided to prepare and investigate quaternized,
imidazolium analogues of 3−5 for several reasons. The first is
that imidazolium oximes are expected to be more water-soluble
than their tertiary counterparts. Second, quaternization of
imidazole nitrogen is expected to change the electronic
configuration of the imidazole ring, significantly alter the
delocalized system, and reduce the level of protonation of the
oxime moiety, thus influencing its nucleophilic reactivity.
Finally, reactivation of the cyclosarin OP−hBChE conjugate
was enhanced significantly by the imidazolium analogue of RS-
113B [conversion of RS-113B to 11 (Table 2)].
Reactivation rate constants of three imidazolium derivatives
along with their tertiary analogues for reactivation of the OP−
hBChE conjugate are listed in Table 3. It appears that for only
one oxime pair and for only cyclosarin-inhibited hBChE was
reactivation enhanced for the quaternary imidazolium, albeit
significantly, by ∼50-fold [difference between 5 and 13 (Table
3)]. Otherwise, all imidazolium aldoximes exhibited slower
reactivation than their tertiary counterparts. More importantly,
however, the series of tertiary imidazole compounds were faster
reactivators than TAB2OH, to the best of our knowledge the
best OP−hBChE conjugate reactivator published to date,11 and
in our preliminary in vivo experiments less toxic to mice (data
not shown). None of the other commonly used pyridinium
aldoximes (HI6, MMB4, TMB4, and obidoxime) showed
comparable general reactivation potencies for the OP−hBChE
conjugates that were tested. The best overall reactivator of all
four OP−hBChE conjugates was 4, being most efficient for the
VX−BChE conjugate and several-fold better than any other
oxime. Its quaternary analogue, 14, was on average ∼70-fold
slower and the slowest of all reactivators in Table 3 for each of
four OP−hBChE conjugates.
Modeling the Oxime−BChE Conjugate. Computational
molecular modeling of reversible interactions of 4 and 14
within the active center gorge of the VX−hBChE conjugate
reveals a higher frequency of reactive oxime orientations for 4
when criteria of lowest interaction energy, shortest distance
between oximate oxygen and conjugated OP phosphorus, and
smallest deviation from the ideal in-line attack geometry are
considered. It appears that for 4 six to seven conformers (#0,
#2, #3, #6, #9, #8, and #5, in improving order) of 10 calculated
conformers showed comparatively productive properties
(Figure 1) and could be matched by only two or three
Figure 1. Computational (MD-simulated annealing) analysis of interaction of oximes 4 and 14 in the active center gorge of the VX−hBChE
conjugate. For each of two oximes, 10 conformers were calculated and analyzed for their total interaction energies, Etotal (shown as the difference
from the lowest-energy conformer ΔEtotal), the distance between the nucleophilic oxime O and conjugated phosphorus (-P···O−NC- distance),
and nucleophilic attack angles: Ser−(O-P···O)−N angle (ideally 180°) and Ser−O−(P···O-N) angle (ideally 109.5°). Horizontal black stripes are
shown to emphasize the difference between two oximes.
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conformers of 14 (#3, #5, and #7) with similar parameters
(Figure 1). Conformers of 14 were consistently found to bind
slightly farther from conjugated phosphorus and significantly
closer to aspartate 70 of hBChE located in the opposite corner
of the hBChE gorge. This is consistent with a Coulombic
attraction between the cationic imidazolium ring and anionic
Asp 70 of ∼4.8 Å that is not possible for the nonprotonated
tertiary imidazole derivative 4, for which the distance was
consequently ∼6.4 Å (Figure 2). Our preliminary computa-
tional analysis thus indicates that this electrostatic interaction
may reduce the reactivation efficiency of imidazolium aldoxime
14 by orienting its tertiary butyl side chain deeper into the
hydrophobic hBChE gorge (Figure 2).
AChE Reactivation potencies. Reactivation rates of OP-
conjugated hAChEs, on the other hand, were relatively slow for
all six imidazole aldoximes (Table 4), consistent with the
severely restricted size of the OP−hAChE gorge where
insertion of hydrophobic side chains of imidazole aldoximes
deeper into the gorge likely forces the oximate group into
positions farther from conjugated phosphorus. Reactivation
rates of imidazoles did not approach those of smaller, cationic
2PAM, except for that of cyclosarin−hAChE conjugate
reactivation by imidazolium aldoximes, 12 and 13, yielding
rates comparable to that of 2PAM. Typically, for AChE,
imidazolium aldoximes were several-fold slower reactivators
than 2PAM and their tertiary analogues even another order of
magnitude slower than 2PAM. Thus, unlike reactivation of
hBChE, charged imidazolium aldoximes were better reactiva-
tors of OP−hAChEs conjugates than tertiary imidazoles
(Figure 3). In comparison with TAB2OH, a poor OP−
hAChE conjugate reactivator, tertiary imidazoles were similarly
poor OP−hAChE conjugate reactivators, but rates were
enhanced by an order of magnitude for quaternary imidazolium
reactivators with OP−hAChE conjugates.
Overall Structure−Activity Comparisons. In our pre-
vious study,11 we demonstrated both in vitro and in vivo
capacities of TAB2OH, an exocyclic cationic, nonpyridinium
aldoxime, to turn over nerve agent OPs catalytically in the
presence of purified hBChE. The superior in vitro reactivation
potency of several imidazole and imidazolium aldoximes against
OP−hBChE conjugates, presented in this study in comparison
with TAB2OH, positions this series of compounds very
favorably for in vivo studies of catalytic OP turnover mediated
by hBChE. The greater than an order of magnitude
enhancement of reactivation rates allows one to consider that
reactivators of this general family or its second-generation
cousins could become sufficiently efficient in vivo to support
enhanced OP degradation even in the absence of exogeneous
administration of purified hBChE. The concentration of
naturally occurring hBChE in human plasma is estimated to
be ∼70 nM,22 and substantial amounts of this enzyme were
detected in lung mucosa and intestine, tissue gateways to
absorption of initial amounts of toxicant upon nerve gas or
pesticide OP exposure.
Furthermore, imidazole aldoximes, as uncharged entities at
physiological pH, should be amenable to a more effective
distribution across biological membranes resulting in enhanced
oral bioavailability compared to those of pyridinium aldoximes.
That would allow them to reach OP-exposed tissue rich in
BChE and establish catalytic OP degradation in situ following a
noninvasive oral administration route.
■ CONCLUSION
Imidazole-based aldoximes are identified in this study as a new
class of efficient hBChE reactivators. Starting with initial leads
Figure 2. Stereo image of imidazole oximes 4 and 14 docked in the active center gorge of the VX−hBChE conjugate represented by the teal
Connolly surface, ribbon, and sticks. Atoms of phosphonyl Ser 198 are represented by sticks (P in orange, C in yellow, and O in red). Oximes are
represented by sticks (N in blue, O in red, and C in yellow for 4 and white for 14). Optimally positioned conformers #7 (14) and #5 (4) of 10
calculated conformers for each oxime are shown. All imidazolium conformers of 14 were positioned noticeably closer to the anionic aspartate 70
(D70) than tertiary imidazole conformers 4. Details of computational results are shown in Figure 1.
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identified from our synthetic library, we refined several highly
efficient tertiary imidazole and quaternary imidazolium
aldoximes to achieve an order of magnitude or more
enhancement of in vitro OP−hBChE conjugate reactivation
rates compared to that of TAB2OH, the most efficient hBChE
reactivator published to date. The reduction of a cationic
species at physiologic pH values and the prospect of good
bioavailability and CNS penetration make tertiary imidazole
aldoximes candidates well suited for toxicity, pharmacokinetic,
and OP exposure efficacy testing in vivo. Thus, we present here
a new family of catalytic bioscavengers of nerve agent and
pesticide OPs that are dependent on hBChE reactivation.
Unlike existing reactivators, these imidazole-based aldoximes
have the potential capacity to enlist endogenous tissue hBChE
and establish catalytic OP degradation directly in the exposed
tissue before lipophilic OPs are distributed into peripheral and
central cholinergic innervated target tissues and cause the
sequelae of cholinergic hyperexcitation.
■ EXPERIMENTAL SECTION
Preparation of Novel Oximes. General. All reactions were
performed with commercially available ACS grade reagents and
solvents. Anhydrous DMF, acetonitrile, and nitromethane were used
as received without further purification. All synthesized compounds
were determined to possess a purity of more than 95%, as evidenced
by high-performance liquid chromatography analysis and 1H nuclear
magnetic resonance (NMR). 1H NMR and 13C NMR spectra were
recorded on a Varian 400 MHz spectrometer. All chemical shifts were
reported in parts per million relative to solvent resonances, as
indicated (DMSO-d6 δ 2.49,
1H; δ 39.49, 13C) (CDCl3 δ 7.26,
1H; δ
77.0, 13C). 1H NMR coupling constants (J) are given in hertz.
General Method A for the Preparation of Imidazole Oximes 3−
10. To a mixture of formylimidazole 1 and K2CO3 in DMF was added
the required bromide or mesylate, and the reaction mixture was stirred
overnight under an atmosphere of nitrogen at room temperature (rt).
The resulting suspension was cooled to rt and filtered. Water was
added to the filtrate, and the resulting solution was extracted with
Et2O (3 × 25 mL). The organic layer was dried over MgSO4 and
evaporated to give the corresponding alkylimidazole-2-carbaldehyde.
Hydroxylamine hydrochloride (1.5 equiv) was dissolved in water
and neutralized with Na2CO3 (1.5 equiv). Alkylimidazole-2-
carbaldehyde was added to the solution of hydroxylamine, and the
reaction mixture was stirred at rt for 1 h. The resulting precipitate of
the corresponding oxime was collected by filtration, rinsed with water,
and dried over P2O5 under vacuum.
1-(Pent-4-en-1-yl)imidazole-2-carbaldehyde Oxime (3). Prepared
according to general method A using formylimidazole 1 (0.50 g, 5.2
mmol), K2CO3 (0.72 g, 5.2 mmol), and 5-bromopent-1-ene (0.93 g,
6.2 mmol) in DMF (20 mL). Yellow oil 2a (0.55 g, 64%).
1-(Pent-4-en-1-yl)imidazole-2-carbaldehyde (2a) (0.50 g, 3 mmol),
NH2OH·HCl (0.31 g, 4.5 mmol), water (5 mL), Na2CO3 (0.48 g, 4.5
mmol): white solid; yield 0.47 g, 87%; 1H NMR (400 MHz, DMSO-
d6) δ 11.46 (s, 1H), 8.04 (s, 1H), 7.31 (s, 1H), 7.00 (s, 1H), 5.85−5.75
(m, 1H), 5.07−4.94 (m, 2H), 4.23 (t, J = 8, 2H), 2.00 (q, J = 8, 2H),
1.77 (pent, J = 8, 2H); 13C NMR (400 MHz, DMSO-d6) δ 141.3,
Table 4. Reactivation Rate Constants of 0.67 mM N-Alkyl-Substituted Imidazole and Imidazolium Aldoximes for OP−hAChE
Conjugates Prepared and Analyzed As Described in Table 3 for OP−hBChE Conjugatesa
aValues for 2PAM and TAB2OH were not included in the evaluation of the kobs average.
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139.6, 137.6, 128.8, 123.7, 115.4, 46.2, 30.0, 29.4; LC−MS (ESI) [M +
H]+ calcd for C9H14N3O m/z 180.2, found m/z 180.3.
1-(3,3-Dimethylbutyl)imidazole-2-carbaldehyde Oxime (4). Pre-
pared according to general method A using formylimidazole 1 (0.50 g,
5.2 mmol), K2CO3 (0.72 g, 5.2 mmol), and 1-bromo-3,3-
dimethylbutane (1 g, 6.2 mmol) in DMF (20 mL). Yellow oil 2b
(0.57 g, 61%).
1-(3,3-Dimethylbutyl)imidazole-2-carbaldehyde (2b) (0.54 g, 3
mmol), NH2OH·HCl (0.31 g, 4.5 mmol), water (5 mL), Na2CO3
(0.48 g, 4.5 mmol): white solid; yield 0.52 g, 89%; 1H NMR (400
MHz, DMSO-d6) δ 11.42 (s, 1H), 8.02 (s, 1H), 7.33 (s, 1H), 6.98 (s,
1H), 4.25 (pent, J = 4, 2H), 1.56 (pent, J = 4, 2H), 0.93 (s, 9H); 13C
NMR (400 MHz, DMSO-d6) δ 141.3, 139.4, 128.8, 123.4, 44.3, 43.6,
29.7, 29.2; LC−MS (ESI) [M + H]+ calcd for C10H18N3O m/z 196.3,
found m/z 196.3.
1-(3-Phenylpropyl)imidazole-2-carbaldehyde Oxime (5). Pre-
pared according to general method A using formylimidazole 1 (0.50
g, 5.2 mmol), K2CO3 (0.72 g, 5.2 mmol), and (3-bromopropyl)-
benzene (1.2 g, 6.2 mmol) in DMF (20 mL). Yellow oil 2c (0.77 g,
69%).
1-(3-Phenylpropyl)imidazole-2-carbaldehyde (2c) (0.64 g, 3
mmol), NH2OH·HCl (0.31 g, 4.5 mmol), water (5 mL), Na2CO3
(0.48 g, 4.5 mmol): white solid; yield 0.58 g, 84%; 1H NMR (400
MHz, DMSO-d6) δ 11.47 (s, 1H), 8.05 (s, 1H), 7.34 (s, 1H), 7.28 (t, J
= 8, 2H), 7.18 (app d, J = 8, 3H), 7.01 (s, 1H), 4.27 (t, J = 8, 2H), 2.55
(t, J = 8, 2H), 1.99 (pent, J = 8, 2H); 13C NMR (400 MHz, DMSO-d6)
δ 141.3, 141.0, 139.6, 128.8, 128.4, 128.1, 125.9, 123.6, 46.5, 32.0, 31.9;
LC−MS (ESI) [M + H]+ calcd for C13H16N3O m/z 230.3, found m/z
230.3.
1-Isopentylimidazole-2-Carbaldehyde Oxime (6). Prepared ac-
cording to general method A using formylimidazole 1 (0.50 g, 5.2
mmol), K2CO3 (0.72 g, 5.2 mmol), and 1-bromo-3-methylbutane
(0.94 g, 6.2 mmol) in DMF (20 mL). Yellow oil 2d (0.61 g, 71%).
1-Isopentylimidazole-2-carbaldehyde (2d) (0.50 g, 3 mmol),
NH2OH·HCl (0.31 g, 4.5 mmol), water (5 mL), Na2CO3 (0.48 g,
4.5 mmol): white solid; yield 0.44 g, 81%; 1H NMR (400 MHz,
DMSO-d6) δ 11.42 (s, 1H), 8.03 (s, 1H), 7.32 (s, 1H), 6.99 (s, 1H),
4.25 (t, J = 8, 2H), 1.59−1.46 (m, 3H), 0.9 (d, J = 4, 6H); 13C NMR
(400 MHz, DMSO-d6) δ 141.4, 139.5, 128.8, 123.5, 45.1, 25.1, 22.3;
LC−MS (ESI) [M + H]+ calcd for C9H16N3O m/z 182.2, found m/z
182.3.
1-(3-Azidopropyl)imidazole-2-carbaldehyde Oxime (7). Prepared
according to general method A using formylimidazole 1 (0.50 g, 5.2
mmol), K2CO3 (0.72 g, 5.2 mmol), and 3-azidopropylmethanesulfo-
nate (1.1 g, 6.2 mmol) in DMF (20 mL). Yellow oil 2e (0.62 g, 67%).
1-(3-Azidopropyl)imidazole-2-carbaldehyde (2e) (0.54 g, 3 mmol),
NH2OH·HCl (0.31 g, 4.5 mmol), water (5 mL), Na2CO3 (0.48 g, 4.5
mmol): white solid; yield 0.46 g, 79%; 1H NMR (400 MHz, DMSO-
d6) δ 11.48 (s, 1H), 8.05 (s, 1H), 7.32 (s, 1H), 7.01 (s, 1H), 4.29 (t, J
= 8, 2H), 3.33 (t, J = 8, 2H), 1.94 (pent, J = 8, 2H); 13C NMR (400
MHz, DMSO-d6) δ 141.3, 139.6, 128.9, 123.7, 47.9, 44.2, 29.4; LC−
MS (ESI) [M + H]+ calcd for C7H11N6O m/z 195.2, found m/z 195.3.
1-(3-Azidobutyl)imidazole-2-carbaldehyde Oxime (8). Prepared
according to general method A using formylimidazole 1 (0.50 g, 5.2
mmol), K2CO3 (0.72 g, 5.2 mmol), and 3-azidobutylmethanesulfonate
(1.2 g, 6.2 mmol) in DMF (20 mL). Yellow oil 2f (0.68 g, 68%).
1-(3-Azidobutyl)imidazole-2-carbaldehyde (2f) (0.58 g, 3 mmol),
NH2OH·HCl (0.31 g, 4.5 mmol), water (5 mL), Na2CO3 (0.48 g, 4.5
mmol): white solid; yield 0.55 g, 88%; 1H NMR (400 MHz, DMSO-
d6) δ 11.54 (s, 1H), 8.06 (s, 1H), 7.33 (s, 1H), 7.02 (s, 1H), 4.26 (t, J
= 8, 2H), 3.34 (t, J = 8, 2H), 1.73 (pent, J = 8, 2H), 1.47 (pent, J = 8,
2H); 13C NMR (400 MHz, DMSO-d6) δ 141.2, 139.5, 128.6, 123.7,
50.2, 46.1, 27.5, 25.3; LC−MS (ESI) [M + H]+ calcd for C8H13N6O
m/z 209.2, found m/z 209.3.
1-(3-Prop-2-yn-1-yl)imidazole-2-carbaldehyde Oxime (9). Pre-
pared according to general method A using formylimidazole 1 (0.50
Figure 3. Summary of reactivation rate constants (kobs) of six 0.67 mM N-alkyl-substituted imidazole oximes for OP−hAChE and OP−hBChE
conjugates formed by inhibition by paraoxon and F1uOP analogues of sarin, cyclosarin, and VX. Gray bars represent data for uncharged tertiary
imidazole aldoximes, white bars data for cationic quaternary imidazolium aldoximes, and black bars data for cationic references, pyridinium aldoxime,
2PAM, and nonpyridinium aldoxime, TAB20H. Data are taken from Tables 3 and 4.
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g, 5.2 mmol), K2CO3 (0.72 g, 5.2 mmol), and an 80 wt % propargyl
bromide solution in toluene (0.67 mL, 6.2 mmol) in DMF (20 mL).
Yellow oil 2g (0.49 g, 70%).
1-(3-Prop-2-yn-1-yl)imidazole-2-carbaldehyde (2g) (0.40 g, 3
mmol), NH2OH·HCl (0.31 g, 4.5 mmol), water (5 mL), Na2CO3
(0.48 g, 4.5 mmol): white solid; yield 0.35 g, 78%; 1H NMR (400
MHz, DMSO-d6) δ 11.61 (s, 1H), 8.06 (s, 1H), 7.39 (s, 1H), 7.03 (s,
1H), 5.14 (d, J = 4, 2H), 3.46 (d, J = 4, 2H); 13C NMR (400 MHz,
DMSO-d6) δ 141.0, 139.5, 129.0, 123.2, 78.8, 76.0, 36.5; LC−MS
(ESI) [M + H]+ calcd for C7H8N3O m/z 150.2, found m/z 150.3.
1-Nonylimidazole-2-carbaldehyde Oxime (10). Prepared accord-
ing to general method A using formylimidazole 1 (0.50 g, 5.2 mmol),
K2CO3 (0.72 g, 5.2 mmol), and 1-bromononane (1.3 g, 6.2 mmol) in
DMF (20 mL). Yellow oil 2h (0.88 g, 76%).
1-Nonylimidazole-2-carbaldehyde (2h) (0.67 g, 3 mmol), NH2OH·
HCl (0.31 g, 4.5 mmol), water (5 mL), Na2CO3 (0.48 g, 4.5 mmol):
white solid; yield 0.60 g, 84%; 1H NMR (400 MHz, DMSO-d6) δ
11.44 (s, 1H), 8.03 (s, 1H), 7.30 (s, 1H), 6.98 (s, 1H), 4.21 (d, J = 8,
2H), 1.66 (t, J = 8, 2H), 1.22 (app s, 12H), 0.84 (t, J = 8, 3H); 13C
NMR (400 MHz, DMSO-d6) δ 141.3, 139.5, 128.6, 123.6, 46.6, 31.3,
30.4, 29.0, 28.6, 25.9, 22.1, 13.9; LC−MS (ESI) [M + H]+ calcd for
C13H24N3O m/z 238.3, found m/z 238.4.
General Method B for the Preparation of Imidazole Oximes 11−
14. To a solution of iodomethane (0.26 g, 1.8 mmol) in nitromethane
(3 mL) was added the corresponding imidazole-2-carbaldehyde oxime
(1.5 mmol), and the reaction mixture was stirred overnight at 50 °C.
The resulting solution was cooled to rt and concentrated, and water (3
mL) was added. An aqueous solution was extracted with chloroform (2
× 2 mL). The organic layer was discarded, and the aqueous layer was
evaporated. The resulting solid was dried over P2O5 under vacuum to
give the corresponding imidazole-2-carbaldehyde oxime quaternary
salt.
2-[(Hydroxyimino)methyl]-3-methyl-1-pentylimidazol-3-ium Io-
dide (11). Prepared according to general method B: white solid;
yield 0.33 g, 69%; 1H NMR (400 MHz, DMSO-d6) δ 12.98 (s, 1H),
8.55 (s, 1H), 7.90 (d, J = 4, 1H), 7.85 (d, J = 4, 1H), 4.32 (t, J = 8,
2H), 3.92 (s, 3H), 1.73 (pent, J = 8, 2H), 1.31−1.22 (m, 4H), 0.85 (t,
J = 8, 3H); 13C NMR (400 MHz, DMSO-d6) δ 136.5, 135.5, 124.6,
123.2, 48.7, 36.7, 29.2, 27.6, 21.6, 13.8; LC−MS (ESI) [M]+ calcd for
C10H18N3O
+ m/z 196.3, found m/z 196.3. An alternative method for
the preparation of this oxime was reported previously.14
2-[(Hydroxyimino)methyl]-3-methyl-1-(pent-4-en-1-yl)imidazol-
3-ium Iodide (12). Prepared according to general method B: white
solid; yield 0.36 g, 74%; 1H NMR (400 MHz, DMSO-d6) δ 12.97 (s,
1H), 8.54 (s, 1H), 7.92 (s, 1H), 7.87 (s, 1H), 5.85−5.75 (m, 1H),
5.05−4.97 (m, 2H), 4.32 (t, J = 8, 2H), 3.92 (s, 3H), 2.05 (q, J = 8,
2H), 1.83 (pent, J = 8, 2H); 13C NMR (400 MHz, DMSO-d6) δ 137.1,
136.6, 135.4, 124.6, 123.2, 115.6, 48.3, 36.7, 29.6, 28.5; LC−MS (ESI)
[M]+ calcd for C10H16N3O
+ m/z 194.3, found m/z 194.3.
2-[(Hydroxyimino)methyl]-3-methyl-1-(3-phenylpropyl)imidazol-
3-ium Iodide (13). Prepared according to general method B: white
solid; yield 0.35 g, 63%; 1H NMR (400 MHz, DMSO-d6) δ 13.01 (s,
1H), 8.56 (s, 1H), 7.90 (d, J = 8, 1H), 7.84 (d, J = 8, 1H), 7.29 (t, J =
8, 2H), 7.20 (d, J = 8, 3H), 4.36 (app s, 2H), 3.91 (s, J = 8, 3H), 2.61
(t, J = 8, 2H), 2.06 (pent, J = 8, 2H); 13C NMR (400 MHz, DMSO-d6)
δ 140.6, 136.7, 135.5, 128.4, 128.1, 126.0, 124.7, 123.2, 48.6, 36.7, 31.6,
31.0; LC−MS (ESI) [M]+ calcd for C14H18N3O+ m/z 244.3, found m/
z 244.3.
1-(3,3-Dimethylbutyl)-2-[(hydroxyimino)methyl]-3-methylimida-
zol-3-ium Iodide (14). Prepared according to general method B: white
solid; yield 0.34 g, 67%; 1H NMR (400 MHz, DMSO-d6) δ 12.97 (s,
1H), 8.52 (s, 1H), 7.93 (d, J = 4, 1H), 7.83 (d, J = 4, 1H), 4.35 (pent, J
= 4, 2H), 3.90 (s, 3H) 1.64 (pent, J = 4, 2H), 0.95 (s, 9H); 13C NMR
(400 MHz, DMSO-d6) δ 136.4, 135.3, 124.6, 123.3, 46.1, 43.1, 40.1,
29.8, 29.0; LC−MS (ESI) [M]+ calcd for C11H20N3O+ m/z 210.3,
found m/z 210.3.
1-(3-Bromopropyl)imidazole-2-carbaldehyde Oxime (16). To a
mixture of formylimidazole 1 (3 g, 31.2 mmol) and K2CO3 (2.2 g, 15.6
mmol) in DMF (50 mL) was added 1,3-dibromopropane (18.9 g, 93.6
mmol) dropwise, and the reaction mixture was stirred overnight under
a nitrogen atmosphere at rt. Water (120 mL) was added to the
resulting suspension, and the solution was extracted with Et2O (3 × 50
mL). The organic layer was dried over MgSO4 and evaporated to give
1-(3-bromopropyl)-1H-imidazole-2-carbaldehyde (15).
Hydroxylamine hydrochloride (3.2 g, 46.8 mmol) was dissolved in
water (20 mL) and neutralized with Na2CO3 (5 g, 46.8 mmol). 1-(3-
Bromopropyl)-1H-imidazole-2-carbaldehyde (15) was added to the
solution of hydroxylamine, and the reaction mixture was stirred at rt
for 2 h. The resulting precipitate of the corresponding oxime 16 was
filtered out, rinsed with water, and dried over P2O5 under vacuum to
yield a white solid: yield 4.3 g, 60%; 1H NMR (400 MHz, DMSO-d6)
δ 11.5 (s, 1H), 8.05 (s, 1H), 7.32 (s, 1H), 7.02 (s, 1H), 4.33 (t, J = 8,
2H), 3.44 (t, J = 8, 2H), 2.23 (pent, J = 8, 2H); 13C NMR (400 MHz,
DMSO-d6) δ 141.2, 139.6, 128.9, 123.6, 45.3, 33.0, 31.0; LC−MS
(ESI) [M + H]+ calcd for C12H15N4O
+ m/z 231.3, found m/z 231.3;
LC−MS (ESI) [M + H]+ calcd for C7H11BrN3O m/z 232.1, found m/
z 232.1, [M + H + 2]+ m/z 234.1.
General Method C for the Preparation of Imidazole Oximes 17
and 18. To a suspension of imidazole-2-carbaldehyde oxime (16)
(0.23 g, 1 mmol) in nitromethane (3 mL) was added the
corresponding pyridine derivative (1.5 mmol), and the mixture was
stirred for 3 days at 50 °C. The resulting solution was cooled to rt and
concentrated. Water (3 mL) was added and the mixture washed with
chloroform (2 × 2 mL). The combined organic layers were discarded,
and the water layer was evaporated and purified on a reversed-phase
biotage using a water/methanol mixture as the eluent. The solvent was
evaporated, and the resulting solid was dried over P2O5 under vacuum
to give the corresponding imidazole-2-carbaldehyde oxime quaternary
salt.
1-(3-{2-[(Hydroxyimino)methyl]-1H-imidazol-1-yl}propyl)pyridin-
1-ium Bromide (17). Prepared according to general method C: brown
solid; yield 0.17 g, 54%; 1H NMR (400 MHz, DMSO-d6) δ 11.46 (s,
1H), 8.05 (s, 1H), 7.33 (s, 1H), 7.27 (t, J = 8, 2H), 7.16 (app d, J = 8,
3H), 7.00 (s, 1H), 4.26 (t, J = 8, 2H), 2.54 (t, J = 8, 2H), 1.98 (pent, J
= 8, 2H); 13C NMR (400 MHz, DMSO-d6) δ 149.9, 149.5, 141.3,
139.6, 128.8, 123.7, 123.6, 46.3, 31.2, 30.5; LC−MS (ESI) [M + H]+
calcd for C12H15N4O
+ m/z 231.3, found m/z 231.3.
4-Carbamoyl-1-(3-{2-[(hydroxyimino)methyl]imidazol-1-yl}-
propyl)pyridin-1-ium Bromide (18). Prepared according to general
method C: brown solid; yield 0.18 g, 51%; 1H NMR (400 MHz,
DMSO-d6) δ 11.52 (s, 1H), 8.60 (s, 1H), 8.08 (s, 1H), 7.84 (2, J = 8,
2H), 7.47−7.31 (m, 4H), 7.07 (s, 1H), 4.39 (t, J = 8, 2H), 4.32 (app s,
2H), 2.34 (app s, 2H); 13C NMR (400 MHz, DMSO-d6) δ 141.3,
141.0, 139.6, 128.7, 128.3, 128.1, 125.9, 123.5, 46.5, 32.0, 31.9; LC−
MS (ESI) [M + H]+ calcd for C13H16N5O2
+ m/z 274.3, found m/z
274.3.
Enzyme. Highly purified recombinant monomeric hAChE (human
AChE) was prepared as described previously.23 Purified human BChE
isolated from human plasma was a gift from D. Lenz and D. Cerasoli
[USAMRICD (U.S. Army Medical Research Institute of Chemical
Defense), Aberdeen Proving Ground, MD]. All enzyme concen-
trations given refer to the concentration of catalytic sites, i.e.,
monomers.
OPs. Low-toxicity nonvolatile Flu-MPs (fluorescent methylphosph-
onates)24 were used as analogues of nerve agents sarin, cyclosarin, and
VX. The Flu-MPs differ from actual nerve agent OPs only by the
structure of their respective leaving groups. Inhibition of hBChE and
hAChE by Flu-MPs results in OP−hBChE and OP−hAChE covalent
conjugates identical with the ones formed upon inhibition with nerve
agents. Paraoxon was purchased from Sigma-Aldrich.
Oximes. 2PAM (2-pyridinealdoxime methiodide) and obidoxime
[1,1′-(oxidimethylene) bis(pyridinium-4-carbaldoxime) dichloride]
were purchased from Sigma-Aldrich. TAB2OH and RS-113A, RS-
113B, RS-115A, RS-115B, and RS-115C were prepared as described
previously.11,12 HI6 was purchased from US Biological. MMB4 and
TMB4 were gifts from T. Shih and I. Koplowitz (USAMRICD).
Reactivation Assays. hAChE and hBChE activities were
measured using a spectrophotometric assay25 at rt in 0.1 M sodium
phosphate buffer (pH 7.4), containing 0.01% BSA and 1.0 mM
substrate ATCh (acetylthiocholine). OP−hBChE and OP−hAChE
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conjugates were prepared using Flu-MPs and paraoxon, and oxime
reactivation experiments were performed at 37 °C in 0.1 M sodium
phosphate buffer (pH 7.4) containing 0.01% BSA, as described
previously.23 The first-order reactivation rate constant (kobs) for each
oxime−OP conjugate combination was calculated by nonlinear
regression.26
Computational Molecular Modeling. Molecular models of
oximes 4 and 14 were built and prepared using the Insight II
modeling suite (Accelrys, San Diego, CA) as described previously for
similar aldoximes.23 The imidazole ring of 4 was not protonated in the
calculation, consistent with the determined pKa of 5.6 (data not
shown). The crystal structure of the VX−hBChE conjugate (Protein
Data Bank entry 2XQK) was prepared for calculation by removing all
water molecules and reversibly bound ligands and repairing
incomplete amino acid side chains. Oximes were positioned into the
VX−hBChE gorge with their oximate oxygens 4 Å from the
conjugated phosphorus atom. A flexible distance constraint was placed
between those two atoms at 3 Å, and molecular dynamics (MD)
calculations were performed at a series of temperatures starting at 300
K, increasing to 700 K, and decreasing to 300 K in 50 K increments, as
described previously for HI6.23 The structure of hBChE (amide
backbone and side chains) was kept fixed because of the relatively large
volume of the VX−hBChE gorge, while oxime molecules were allowed
to freely rotate. Ten calculations were performed per oxime. Resulting
structures were visualized using Discovery Studio Visualizer version 3.5
(Accelrys).
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(20) Primozǐc,́ I.; Odzǎk, R.; Tomic,́ S.; Simeon-Rudolf, V.; Reiner, E.
Pyridinium, imidazolium, and quinuclidinium oximes: Synthesis,
interaction with native and phosphorylated cholinesterases, and
antidotes against organophosphorus compounds. Journal of Medical
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm401650z | J. Med. Chem. 2014, 57, 1378−13891388
Chemical, Biological and Radiological Defense 2004, 2, http://www.
jmedcbr.org/Issue_0201/Reiner_0704.pdf.
(21) Reiner, E.; Simeon, V. Pyridinium, imidazolium and
quinuclidinium compounds: Toxicity and antidotal effects against
the nerve agents tabun and soman. Arh. Hig. Rada Toksikol. 2006, 57,
171−179.
(22) Geng, L.; Gao, Y.; Chen, X.; Hou, S.; Zhan, C. G.; Radic,́ Z.;
Parks, R. J.; Russell, S. J.; Pham, L.; Brimijoin, S. Gene transfer of
mutant mouse cholinesterase provides high lifetime expression and
reduced cocaine responses with no evident toxicity. PLoS One 2013, 8,
e67446.
(23) Cochran, R.; Kalisiak, J.; Kucukkilinc, T.; Radic,́ Z.; Garcia, E.;
Zhang, L.; Ho, K. Y.; Amitai, G.; Kovarik, Z.; Fokin, V. V.; Sharpless,
K. B.; Taylor, P. Oxime-assisted acetylcholinesterase catalytic
scavengers of organophosphates that resist aging. J. Biol. Chem.
2011, 286, 29718−29724.
(24) Amitai, G.; Adani, R.; Yacov, G.; Yishay, S.; Teitlboim, S.;
Tveria, L.; Limanovich, O.; Kushnir, M.; Meshulam, H. Asymmetric
fluorogenic organophosphates for the development of active organo-
phosphate hydrolases with reversed stereoselectivity. Toxicology 2007,
233, 187−198.
(25) Ellman, G. L.; Courtney, K. D.; Andres, V., Jr.; Featherstone, R.
M. A new and rapid colorimetric determination of acetylcholinesterase
activity. Biochem. Pharmacol. 1961, 7, 88−95.
(26) Kovarik, Z.; Radic,́ Z.; Berman, H. A.; Simeon-Rudolf, V.;
Reiner, E.; Taylor, P. Mutant cholinesterases possessing enhanced
capacity for reactivation of their phosphonylated conjugates.
Biochemistry 2004, 43, 3222−32229.
Journal of Medicinal Chemistry Article
dx.doi.org/10.1021/jm401650z | J. Med. Chem. 2014, 57, 1378−13891389
